Investor Relations

Financial Transparency
for Institutional Investors

24 consecutive profitable quarters. Real-time operational data, SEC filings, and earnings information for InterCure Ltd. (NASDAQ: INCR / TASE: INCR).

$85M
FY2024 Revenue
12% YoY
$8M
FY2024 EBITDA
~10% Margin
24
Profitable Quarters
Consecutive
25+
Active Pharmacies
IL & DE
Press Releases SEC Filings Financials Governance

Latest News

Press Releases

Selected announcements from InterCure Ltd. All filings and disclosures are available on the MAYA TASE platform.

Loading…
View all press releases on MAYA TASE →

Regulatory Filings

SEC Filings

All filings submitted to the U.S. Securities and Exchange Commission. Data fetched live from SEC EDGAR.

Document Type Filed Period
Loading filings from SEC EDGAR…
View on SEC EDGAR →

Financial Performance

Annual Results Summary

Selected financial data from InterCure's audited annual reports. All figures in USD millions unless noted.

Metric FY2021 FY2022 FY2023 FY2024
Revenue $38M $54M $76M $85M
Gross Profit $16M $22M $32M $38M
Gross Margin 42% 41% 42% 45%
EBITDA $3.1M $4.8M $6.4M $8.0M
EBITDA Margin 8.2% 8.9% 8.4% 9.4%
Active Pharmacies (EOP) 11 17 22 25+

* USD figures are approximate conversions from NIS at prevailing exchange rates. EOP = End of Period. See Form 20-F for audited figures.

Corporate Governance

Governance Documents

InterCure is committed to the highest standards of corporate governance. Key policies and committee charters are available below.

Code of Business Conduct and Ethics
Standards of conduct expected of all directors, officers, and employees. Covers conflicts of interest, confidentiality, and compliance obligations.
View document →
Audit Committee Charter
Defines the purpose, composition, authority, and responsibilities of the Audit Committee of the Board of Directors.
View document →
Compensation Committee Charter
Outlines the mandate and authority of the Compensation Committee, including oversight of executive compensation and equity plans.
View document →
Nominating and Corporate Governance Committee Charter
Establishes the function and responsibilities of the Nominating and Corporate Governance Committee.
View document →
Pending
Compensation Policy
Executive and director compensation framework. Currently under board review.
Pending Amendment
Insider Trading Policy
Prohibitions and procedures for trading in company securities by directors, officers, and employees. Amendment in progress.
Pending
Clawback Policy
Recovery of incentive-based compensation in the event of a financial restatement.
Pending
Investment Policy
Guidelines for management of the company's cash and short-term investment portfolio.
Pending
Whistleblower Policy
Procedures for reporting concerns about accounting, auditing, or ethics matters without fear of retaliation.

Get in Touch

Investor Relations Contact

For investor inquiries, analyst briefings, or additional financial information, please contact our IR team directly.

Email IR Team View SEC Filings
InterCure Ltd.  |  85 Medinat Hayehudim, Herzliya, Israel
NASDAQ: INCR  |  TASE: INCR